This data processing allowed us to identify general chemoresistance mechanisms independent of: (1) the specific PARPi, (2) BRCA1 or BRCA2 deficiency, (3) the type of screen (shRNA- or CRISPR-based), (4) the species (mouse or human), or (5) the anti-cancer agent used (PARPi or cisplatin). Here, BRCA2 is linked to cancer.